Alessa Therapeutics is developing localized drug-eluting implants for the sustained delivery of anti-androgen therapy directly to prostate tumors, minimizing systemic exposure. This approach targets prostate diseases, addressing the need for more effective and tolerable treatment options for patients with prostate cancer and benign prostate hyperplasia.

Asher Bio develops cis-targeted immunotherapies designed to selectively activate specific immune cell types for therapeutic benefit. This platform engages two molecules on the same cell to achieve high selectivity, optimizing efficacy while minimizing off-target toxicity. The lead candidate is a cis-targeted IL-2 therapy specifically activating CD8+ effector T cells.

Avexegen Therapeutics is developing targeted biologic therapies for gastrointestinal disorders, utilizing advanced peptide-based drug delivery systems to enhance therapeutic efficacy. The company focuses on conditions such as inflammatory bowel disease and irritable bowel syndrome, aiming to improve patient outcomes through precise treatment mechanisms.

Avvio Medical provides an office‑based lithotripsy system that uses low‑pressure ultrasound and calcium‑targeted microbubbles to fragment kidney and ureteral stones without anesthesia or stents. The portable console integrates real‑time imaging, automated safety interlocks, and a dedicated CPT code, enabling urologists and ambulatory surgery centers to perform same‑day, cost‑effective stone removal in standard examination rooms.

Bolt Threads develops sustainable biomaterials, such as Mylo made from mycelium and Microsilk derived from spider silk proteins, using biotechnology and fermentation processes. These materials provide eco-friendly alternatives to traditional leather and textiles, addressing the environmental impact of the fashion and beauty industries.

This clinical-stage biopharmaceutical company develops allogeneic cell therapies for serious diseases using proprietary genome-editing technology. Their chRDNA platform enables precise, complex genome editing for creating "off-the-shelf" CAR-T cell therapies. The company focuses on armoring these cell therapies through strategies like immune cloaking to enhance anti-disease activity.

Cell Microsystems provides the CellRaft AIR platform, an air‑based micro‑raft system that automates high‑throughput isolation, culture, and real‑time monitoring of single cells and 3‑D organoids. By eliminating high‑pressure sorting and manual dilution, the platform increases viable clone yields several‑fold and cuts clone generation time by about 50%, while offering imaging‑guided selection and rapid retrieval for downstream assays. It serves academic labs, biotech firms, and pharma R&D teams needing efficient single‑cell or organoid cloning for gene‑editing and therapeutic development.

Circle Pharma designs and develops bioavailable macrocyclic peptide therapeutics targeting intracellular protein-protein interactions, particularly those involved in cancer. Their computational structure-based design approach combines physics-based conformational modeling and innovative chemistry to create permeable macrocyclic peptide drug candidates.

Dren Bio is a clinical‑stage biopharmaceutical company that develops antibody therapeutics designed to selectively deplete pathogenic cells using its proprietary Targeted Myeloid Engager and Phagocytosis Platform. Its pipeline includes two first‑in‑class clinical programs for oncology and autoimmune diseases, plus preclinical candidates across oncology, immunology, and neurology, aiming to improve efficacy while reducing off‑target toxicity.

The startup develops novel analgesics that target the brain's opioid peptide system to restore the brain reward system's function. This approach aims to treat neurobehavioral symptoms associated with compulsivity, self-injury, and addiction in patients, providing access to effective therapeutic options.

Glycomine is developing GLM101, a mannose-1-phosphate replacement therapy currently in clinical trials for PMM2-CDG, a rare genetic disease caused by glycosylation defects. This therapy aims to restore the missing biochemical function, offering potential disease modification rather than merely symptomatic relief.

The startup specializes in needle-free disease monitoring using advanced biosensor technology that analyzes biomarkers through the skin. This approach eliminates the discomfort and risks associated with traditional blood sampling, providing a more patient-friendly method for continuous health monitoring.

Invenio Imaging provides the NIO Laser Imaging System utilizing Stimulated Raman Histology for rapid tissue evaluation. This system delivers high-quality, unstained histology images in under three minutes directly in the operating room. The native digital images support immediate intraoperative decision-making and allow for subsequent downstream analysis of the retrieved tissue sample.

Kit is an email marketing and automation platform designed specifically for creators to manage subscribers and scale their knowledge business. The platform provides tools for list growth via landing pages and forms, alongside visual automations to nurture relationships and drive sales. Creators can also monetize their audience directly through commerce features for digital products and paid newsletters.

Mammoth Biosciences develops CRISPR-Cas-based gene editing therapeutics and diagnostics to enable precise in vivo applications for serious diseases and molecular detection. Their technology addresses the challenges of gene delivery and expands testing capabilities, providing permanent solutions for unmet medical needs.